• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Innoviva Inc.

    5/4/26 4:59:04 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INVA alert in real time by email
    8-K
    false 0001080014 0001080014 2026-05-04 2026-05-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 4, 2026

     

     

    INNOVIVA, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   000-30319   94-3265960

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

    1350 Old Bayshore Highway,

    Suite 400

    Burlingame, California

    94010

    (650) 238-9600

    (Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

     

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   INVA   The NASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2027, as follows:

     

    Members

       Number of
    Shares Voted
    For
         Number of
    Shares Voted
    Against or
    Abstained
         Broker
    Non-Votes
     

    Derek Small

         56,752,327        2,485,600        6,809,010  

    Mark A. DiPaolo, Esq.

         50,072,119        9,165,808        6,809,010  

    Jules Haimovitz

         56,834,625        2,403,302        6,809,010  

    Sarah J. Schlesinger, M.D.

         53,509,479        5,728,448        6,809,010  

    Pavel Raifeld

         58,880,013        357,914        6,809,010  

    At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 56,243,880 shares for, 2,836,001 shares against, 158,046 shares abstaining, and 6,809,010 shares of broker non-votes.

    Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 66,008,453 shares for, 16,574 shares against, 21,910 shares abstaining and 0 broker non-votes.

    At the Meeting, our stockholders also approved Innoviva’s 2026 Equity Incentive Plan. The vote for such approval was 55,435,111 shares for, 3,766,788 shares against, 36,028 shares abstaining, and 6,809,010 shares of broker non-votes.


    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        INNOVIVA, INC.
    Date: May 4, 2026     By:  

    /s/ Pavel Raifeld

          Pavel Raifeld
          Chief Executive Officer
    Get the next $INVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INVA

    DatePrice TargetRatingAnalyst
    2/17/2026$35.00Buy
    BTIG Research
    9/30/2025$17.00Sell
    Goldman
    8/11/2025$45.00Outperform
    Oppenheimer
    7/14/2025$40.00Buy
    H.C. Wainwright
    7/11/2025$26.00Overweight
    Cantor Fitzgerald
    3/7/2025$55.00Sector Outperform
    Scotiabank
    6/18/2024Overweight
    Cantor Fitzgerald
    7/20/2022$16.00Neutral
    Goldman
    More analyst ratings

    $INVA
    SEC Filings

    View All

    SEC Form 8-K filed by Innoviva Inc.

    8-K - Innoviva, Inc. (0001080014) (Filer)

    5/18/26 4:21:36 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.

    SCHEDULE 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    5/13/26 5:21:55 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Innoviva Inc.

    10-Q - Innoviva, Inc. (0001080014) (Filer)

    5/6/26 4:29:28 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares and was granted 1,123 shares, decreasing direct ownership by 0.00% to 285,929 units (SEC Form 4) to satisfy withholding tax

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:12 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Basso Stephen was granted 1,123 shares and covered exercise/tax liability with 559 shares, increasing direct ownership by 0.64% to 88,571 units (SEC Form 4) to satisfy withholding tax

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:16 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 57,516 units (SEC Form 4) (for withholding tax)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/26 4:15:09 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innoviva to Participate in Upcoming Investor Conferences

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Format: Fireside chat Date: Monday, June 8, 2026 Time: 1:20 p.m. Eastern Time BTIG Infectious Disease Day Format: 1x1 meetings Date: Tuesday, June 16, 2026 A live webcast of the Goldman Sachs fireside chat can be accessed under "Ev

    6/1/26 11:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

    Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.

    5/6/26 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. E.T. The conference will be held virtually. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentati

    2/19/26 8:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Innoviva with a new price target

    BTIG Research initiated coverage of Innoviva with a rating of Buy and set a new price target of $35.00

    2/17/26 7:51:08 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Innoviva with a new price target

    Goldman initiated coverage of Innoviva with a rating of Sell and set a new price target of $17.00

    9/30/25 8:55:53 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Innoviva with a new price target

    Oppenheimer initiated coverage of Innoviva with a rating of Outperform and set a new price target of $45.00

    8/11/25 10:03:31 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Leadership Updates

    Live Leadership Updates

    View All

    Innoviva Appoints Stephen Basso as Chief Financial Officer

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

    8/25/23 4:52:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

    Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

    7/11/23 8:00:00 AM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Innoviva Announces Retirement of Board Chairman

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v

    4/28/23 5:30:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Financials

    Live finance-specific insights

    View All

    Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

    Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.

    5/6/26 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

    Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achieve

    11/5/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

    Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,

    8/6/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Innoviva Inc.

    SC 13G - Innoviva, Inc. (0001080014) (Subject)

    5/13/24 1:58:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Innoviva Inc.

    SC 13D - Innoviva, Inc. (0001080014) (Subject)

    5/8/24 3:38:11 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care